Commercialization building with large pharma contracts secured Further progress on next generation sequencing assays for DNA ...

Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot ...

Yet, I assess that Viking Therapeutics’s main growth vector will likely be imputed to its ability to commercialize and ...